Issue Date: December 12, 2017
Issued by: Center for Drug Evaluation and Research
Topic(s): Labeling
Status: Draft
Gluten in Drug Products and Associated Labeling Recommendations; Draft Guidance for Industry
This guidance is intended to convey to drug manufacturers FDA’s recommendations on how certain drug products should be labeled regarding gluten, a matter of interest to individuals with celiac disease. Some individuals with celiac disease have faced difficulty when trying to determine whether specific drug products contain gluten. Confronted by uncertainty, some patients may forego important medication rather than risk an adverse reaction to gluten. Thus, even if gluten is not present at levels that would harm a typical individual with celiac disease, that individual may be harmed through uncertainty and lack of information.
Download the Guidance Document
